Abstract The NCI-MATCH (Molecular Analysis for Therapy Choice) trial (NCT02465060) was
launched in 2015 as a genomically driven, signal-seeking precision medicine platform trial …

Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …

Intratumor heterogeneity (ITH) profoundly affects therapeutic responses and clinical
outcomes. However, the widespread methods for assessing ITH based on genomic …

CD19-directed chimeric antigen receptor (CAR-19) T cells are groundbreaking
immunotherapies approved for use against large B-cell lymphomas. Although host …

Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC),
either in combination or monotherapy. However, there are still some patients who cannot …

Normal cell counterparts of solid and myeloid tumors accumulate mutations years before
disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain …

In the current era of T cell–based immunotherapies, it is crucial to understand which types of
MHC-presented T cell antigens are produced by tumor cells. In addition to linear peptide …

Tumor tissues are constituted by a dynamic diversity of malignant and non-malignant cells,
which shape a puzzling biological ecosystem affecting cancer biology and response to …

Introduction Small-cell lung cancer (SCLC) accounts for 15% of lung cancers and has a
dismal prognosis due to early dissemination and acquired chemoresistance. The initial good …

Intra-tumor heterogeneity (ITH) was a potential mechanism of progression and drug
resistance in bladder cancer (BCa). However, the understanding of ITH in BCa remains …